MSON - Earnings announcements

FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:  Three Months Ended Years Ended  June 30, June 30,   2021   2020   2021  2020          Revenue$19,685,141  $13,713,231  $74,024,073 $62,483,651  Gross profit$14,075,377  $9,432,383  $52,636,255 $43,709,483  Gross profit percentage 71.5%  68.8%  71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91

Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower ExtremityEnhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical OutcomesDeepens Restorative Therapies Vertical by Adding Regenerative Medicine Wound ProductsBioventus and Misonix Management to Host Joint Conference Call Today at 4:30 p.m. Eastern Time DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine

DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Quarter Net Sales: Net Sales of $108 million to $110 million represents 86.2% to 89.7% year-over-year growth and comprises: Net sales from legacy Bioventus Inc. of $96.5 million to $98.0 million, representing organic year-over-year revenue growth* of 66.4% to 69.0%, andNet sales from the acquisition of Bioness Inc. of $11.5 million to $12.0 million. Updated Full-Year 2021 Net Sales Guidance: For the twelve